NCT02663089 - A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 8, 2016

Primary Completion Date

March 17, 2016

Study Completion Date

March 17, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

[14C]-GSK961081 solution for IV infusion

Subjects will receive 10 mL of solution equivalent to 4 mcg of \[14C\]-GSK961081 (approximately 6.2 kilobecquerel \[kBq\]) intravenously as a single dose over 1 hour.

DRUG

[14C]-GSK961081 oral solution

Subjects will receive 10 mL of solution equivalent to 200 mcg of \[14C\]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.

DRUG

GSK961081 dry powder for inhalation

Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London